Medications During Infancy May Shape Future Allergy Risk
Exposure to acid-suppressive medications or antimicrobials in infancy was linked to higher risks for food allergies and anaphylaxis in early childhood, with the risks increasing further with multiple antimicrobial prescriptions.
METHODOLOGY:
Researchers conducted a retrospective study using the US TriNetX Network to examine whether the use of acid-suppressive medications or antimicrobials during infancy influences the risk of developing allergic diseases in childhood.
They identified infants who were prescribed proton pump inhibitors (PPIs; n = 15,375), histamine 2 receptor antagonists (H2RAs; n = 42,913), at least one antibiotic course (n = 740,121), or three or more antibiotic courses (n = 163,098) during the first year of life and compared them with 1,510,074 infants who received none of these medications during their first 2 years.
Three allergic outcomes, namely anaphylaxis, food allergy, and atopic dermatitis, were assessed at 2 years of age.
TAKEAWAY:
Infants prescribed PPIs during their first year of life had more than a fivefold higher risk for food allergy (risk ratio [RR], 5.33; 95% CI, 4.97-5.71) and nearly a 2.5-fold higher risk for anaphylaxis (RR, 2.49; 95% CI, 1.40-4.41) by 2 years of age than unexposed infants.
Similarly, infants prescribed H2RAs had a 4.2-fold higher risk for food allergy (RR, 4.21; 95% CI, 4.01-4.41), a 1.4-fold higher risk for atopic dermatitis (RR, 1.41; 95% CI, 1.35-1.48), and nearly a 4.5-fold higher risk for anaphylaxis (RR, 4.48; 95% CI, 3.43-5.86) than unexposed infants.
Infants with at least one antimicrobial prescription during infancy showed nearly twice the risk for food allergy and more than twice the risk for both atopic dermatitis and anaphylaxis than unexposed infants.
Infants who received three or more antimicrobial prescriptions in their first year faced sharply elevated 2-year risks compared with unexposed infants — nearly 2.8-fold for food allergy, 3.4-fold for atopic dermatitis, and 3.7-fold for anaphylaxis.
IN PRACTICE:
'The composition of the gut microbiota is strongly associated with allergic manifestations, as the commensal bacteria in the gastrointestinal tract promote healthy development of the gut immune system with promotion of food tolerance,' the study authors wrote. 'Antibiotic exposure disrupts these microbial communities, which in turn affects individuals' immune response and likely increases their susceptibility for allergic manifestations,' they added.
SOURCE:
Mohamad R. Chaaban, with the Head & Neck Institute, Cleveland Clinic, Cleveland, was the corresponding author of the study, which was published online on May 30 in the Journal of Clinical Medicine .
LIMITATIONS:
The misdiagnosis of infant food allergies as gastroesophageal reflux disease and higher acid-suppressive medication use in more severe cases may have confounded the associations between these medications and food allergy.
DISCLOSURES:
This project was supported in part by the Clinical and Translational Science Collaborative of Northern Ohio, which is funded by the National Center for Advancing Translational Sciences of the National Institutes of Health. The authors reported having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Penumbra may gain market share in peripheral embolisation coils with Ruby XL
Penumbra has announced US Food and Drug Administration approval for its Ruby XL system, which includes three coils: the Ruby XL, the POD XL and the Packing Coil XL. The Ruby XL coil is a device used in vascular embolisation, a procedure to block or close off blood vessels, and can be used to frame large aneurysms, while the POD XL is designed for use in high-flow vessels and the Packing Coil XL is designed to adjust to the shape of any vessel up to 70cm in length. All Ruby XL system coils can be delivered through a 0.035-inch diagnostic catheter. The system is expected to enable Penumbra to increase its market share in peripheral embolisation coils, according to leading data and analytics company GlobalData. According to GlobalData's US healthcare facility invoicing database, Penumbra currently holds the majority market share for peripheral embolisation coils. Its new coil system allows for peripheral embolisation procedures to be done on a wider range of aneurysm sizes and in longer vessels. If the Ruby XL coil is widely adopted by physicians, Penumbra may be able to capture half the entire market. The approval of the new coil could put a bigger gap between Penumbra and its competitors in the market. Physicians may choose Ruby XL coils for their procedures in order to gain better control of large aneurysms. The Ruby XL system may come with cost savings for consumers as it delivers more volume per coil than other available coils. The average selling price (ASP) of these coils ranges from approximately $900 to $2,000. Already in the middle of this range with its current coils, Penumbra has a competitive advantage for new products. If they come in with a competitive ASP, Penumbra may displace competitor coils for relevant procedures. Penumbra stands to maintain its market lead and possibly increase its market share as the purchasing of the Ruby XL system begins. GlobalData will continue to monitor market trends as purchasing picks up. It is expected that facilities will begin purchasing these coils in June 2025. "Penumbra may gain market share in peripheral embolisation coils with Ruby XL" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
SlimJaro Advanced Weight Loss Supplement in 2025: Can Targeting Inflammation Extra Body Fat, Read Slim Jaro Benefits & Side Effects
SlimJaro Supplement Focused Approach to Fat Burn and Weight Management in 2025 Slimjaro New York City, NY, June 20, 2025 (GLOBE NEWSWIRE) --In 2025, weight loss has become more complicated than simply cutting calories or hitting the gym. Many people around the world are following standard health advice yet still struggle with slow or stagnant results. A growing group of health researchers believe the answer may lie deeper — in inflammation. At the center of this shift is SlimJaro, a new inflammation-focused supplement that aims to help the body naturally release stored fat by targeting internal blockages rather than relying on extreme diets or stimulants. While traditional 'eat less, move more' advice still holds merit, new insights suggest that the body's ability to burn fat is not just about math — it's also about biology. Inflamed fat cells, hormone imbalances, chronic stress, and poor digestion may all play a role in keeping fat 'locked' in place, even when lifestyle changes are made. Why Weight Loss in 2025 Is Harder Than Ever Despite more awareness around healthy eating and exercise, obesity rates remain high across all age groups. Part of the reason is that weight loss has historically focused on symptoms (like appetite or cravings) rather than causes. But new science is revealing some hidden factors:Chronic Inflammation: When fat cells become inflamed — often due to stress, poor diet, environmental toxins, or metabolic syndrome — they can become 'resistant' to fat-burning signals. Cortisol and Insulin Spikes: High stress raises cortisol, which encourages fat storage, especially around the belly. Meanwhile, insulin spikes from processed food can prevent fat breakdown. Poor Digestion and Gut Health: An unbalanced gut microbiome, frequent bloating, or sluggish digestion may impair nutrient absorption and keep metabolism slow. Sleep and Hormones: Lack of sleep and irregular routines disrupt hormonal rhythms that govern hunger and fat storage. This complexity has led many to explore new types of support tools — not to replace diet and exercise, but to work with the body's deeper processes. What Is SlimJaro? According to the official product website (https::// SlimJaro is a U.S.- made, non-GMO dietary supplement designed to support weight management by calming inflammation in the body, particularly in fat tissue. Unlike fat burners loaded with caffeine or synthetic ingredients, SlimJaro relies on plant-based extracts that support metabolism, digestion, and hormone than acting as a quick fix, it aims to act gently over time — restoring balance to systems that are often overlooked in conventional weight loss Makes SlimJaro Different? SlimJaro's approach is unique for a few reasons:Targets Inflammation in Fat Cells: Uses anti-inflammatory compounds like Boswellia, MSM, and Reishi Mushroom to calm fat tissue and support fat release. Mild Thermogenic Effect: Ingredients like Ginger Root gently boost metabolic rate without causing anxiety or heart racing. Digestive Support: Aloe Vera and other plant compounds support gut function, helping reduce bloating and promote regularity. • Stress & Hormonal Balance: Adaptogens like Reishi Mushroom may help regulate cortisol levels, which are often elevated in those who experience stubborn ingredient was selected based on its potential to work with the body rather than against it — aiming to reduce the biological resistance many people face when trying to lose Ingredients and Their Functions Ingredient Primary Role MSM (Methylsulfonylmethane) Anti-inflammatory, supports detox and cell health. Helps release fat stored in inflamed cells. Ginger Root Powder Boosts mild thermogenesis, helps regulate appetite and digestion. Boswellia Serrata Reduces systemic inflammation and supports gut and joint health. Ganoderma Lucidum (Reishi) Modulates stress hormones like cortisol, improves immune balance. Aloe Vera Extract Supports digestion, eases bloating, promotes a healthy gut lining. Arnica Montana Enhances circulation, may support nutrient delivery and tissue recovery. Magnesium (from Epsom Salt) Supports nerve and muscle function, sleep, and blood sugar control. This formulation is manufactured in a GMP-certified and FDA-registered facility in the U.S., with third-party testing to ensure quality and safety. What the Science Suggests Emerging research supports the connection between inflammation and obesity. A 2024 review published in Frontiers in Endocrinology noted that 'chronic low-grade inflammation in adipose tissue plays a key role in obesity-related metabolic dysfunction.' When fat cells are inflamed, they hold onto stored lipids, making it harder to lose weight even with caloric claims to address this root cause. While more peer-reviewed studies are needed on the specific formulation, the individual ingredients have shown promise in early Real Users Are Saying Early adopters of SlimJaro report a mix of outcomes:Many users say they noticed less bloating, steadier appetite, and improved energy within the first 2–3 weeks. A few report modest fat loss, especially around the midsection, without changing their diet significantly. Others did not experience noticeable changes and suggest it works better when paired with healthy SlimJaro has earned attention for its lack of stimulant side effects — no racing heart, nausea, or insomnia, which are common with traditional fat Might Benefit from SlimJaro? SlimJaro Supplement may be worth exploring for individuals who:Struggle with weight loss despite eating healthy and exercising Have signs of chronic inflammation (joint pain, bloating, fatigue) Experience stress-related eating or cortisol imbalance Prefer a gentle, stimulant-free supplement that supports long-term healthOf course, it's always recommended to consult with a healthcare provider before starting any new supplement. Visit SlimJaro Official Website To Read More.. Final Thoughts on Slim Jaro Supplement: A New Path in Weight Management? While SlimJaro is not a miracle pill, its inflammation-centered approach represents a promising shift in how we think about body weight, metabolism, and wellness in 2025. As research continues to uncover the connections between inflammation, gut health, hormones, and fat storage, supplements like SlimJaro may serve as part of a more personalized and effective path to long-term weight and Contact InformationContact: Slimjaro Website: https::// Address: PO Box 90129, Lakeland, FL 33804, USA Phone: +1.833.746.6887 or +1.833.746.5587 Email: support@ -------- Contact Us for Advertising: rajneesh08verma@ Attachment Slimjaro CONTACT: Contact: Slimjaro Website: https::// Address: PO Box 90129, Lakeland, FL 33804, USA Phone: +1.833.746.6887 or +1.833.746.5587 Email: support@
Yahoo
an hour ago
- Yahoo
The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes CHICAGO, June 20, 2025 /PRNewswire/ -- Recent developments for the new Standards of Care in Overweight and Obesity guidelines, the first clinical guidance of its kind, were presented during the Standards of Care in Overweight and Obesity 2025 Updates symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. The Obesity Association™, a division of the ADA, recently announced the publication of Weight Stigma and Bias: Standards of Care in Overweight and Obesity—2025, along with the Introduction & Methodology section in BMJ Open Diabetes Research & Care. This comes at a time when about 110 million American adults are impacted by obesity. Further, up to (53%) of new cases of type 2 diabetes are attributed to obesity every year, demonstrating the need for comprehensive, evidence-based guidelines to inform care. The symposium highlighted key insights on physician guidelines for weight stigma and bias, including training for health care professionals, creating inclusive clinical environments, person-centered communication, shared decision making, and evidence-based interventions. Additionally, researchers highlighted what is next for the clinical guidelines, including a potential section for pharmacologic treatment and a preview of what is going to be covered in that section. The Standards of Care in Overweight and Obesity 2025 Updates symposium is one of many obesity-related symposia and abstracts at the 85th Scientific Sessions, spanning basic through clinical and implementation science. Additional studies highlighting groundbreaking developments obesity treatment and care to be presented at ADA's annual meeting include: Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes—A 52-Week Phase 2 Study ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) Trial Outcomes Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide PATHWEIGH Trial—Building the Highway for Weight Management in Primary Care First Report of a Phase 3 RCT of Orforglipron, a Small Nonpeptide GLP-1RA, as Monotherapy in Drug-Naïve Type 2 Diabetes with Inadequate Glycemic Control—The ACHIEVE-1 Trial Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials "The ADA's Standards of Care in Diabetes guideline is the gold standard for diabetes care and management," said Raveendhara Bannuru, MD, PhD, the ADA's vice president, medical affairs and lead author of the guidelines. "The new Standards of Care in Overweight and Obesity guidelines stand to yield significant impact and progress in patient care, and it's only just the beginning." As part of the ADA's ongoing commitment to combating obesity, new clinical practice guidelines and initiatives are continually being developed to advance the quality of care. Research presentation details:Dr. Bannuru and other Professional Practice Committee members will present these findings at the symposium: Standards of Care in Overweight and Obesity 2025 Updates Friday, June 20 from 12:45–1:45 p.m. About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the Obesity Association Obesity is an epidemic that demands both attention and action. The Obesity Association, a division of the American Diabetes Association, is dedicated to reducing the prevalence of obesity and improving health outcomes. Through a focus on education, action, and evidence-based support, we strive to create a world where people affected by obesity can thrive. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio
